Patents Examined by Richard Schnizer
  • Patent number: 11319541
    Abstract: The present invention is directed to a method of treating cancer using interfering RNA duplexes to mediate gene silencing. The present invention is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: May 3, 2022
    Assignee: PHYZAT BIOPHARMACEUTICALS, LDA.
    Inventor: Patricio Soares da Silva
  • Patent number: 11312964
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: April 26, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 11299733
    Abstract: Methods and compositions directed to altering a population of sRNAs in a sperm using vesicles isolated from an epididymosome are provided. Methods and compositions directed to altering a population of sRNAs in an oocyte using vesicles isolated from an epididymosome are also provided. Methods for altering an sRNA population in a sperm or an oocyte can be used to prevent, or reduce the severity of, a disease, disorder, or condition that would otherwise be inherited by progeny. For example, certain epigenetic inherited conditions due to paternal effects, such as certain metabolic and stress disorders and conditions, can be ameliorated in progeny using sperm or oocytes having an altered sRNA population.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: April 12, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Oliver Rando, Upasna Sharma, Colin Conine
  • Patent number: 11300519
    Abstract: Provided herein are surface enhanced Raman scattering (SERS)-active reagents and methods for detecting one or more analyte in a sample. Said SERS-active reagents are adaptable, sensitive, and easy-to-use in the diagnosis of infectious diseases in a patient, or the detection of toxins, bacteria, viruses, pathogens, hormones, cytokines, antigens, antibodies or illicit drugs in a biological sample. Such methods may be handled by police, soldiers, or health care workers in the field, and do not require specialized training.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: April 12, 2022
    Assignee: Ionica Sciences
    Inventors: Joel S. Tabb, Omar Green
  • Patent number: 11286482
    Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 29, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Scott Lentini, Christopher S. Theile, Martin Maier, Ivan Zlatev
  • Patent number: 11286481
    Abstract: The present invention provides a method for efficiently obtaining a complex in which a gene (mRNA) and a peptide as a translation product thereof are linked via a peptide receptor molecule, and utilization thereof. In the method of the present invention, at least one 2?-modified nucleoside derivative is introduced into a 5? end side of an antisense strand of a template DNA.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 29, 2022
    Assignee: CUBICSTARS, INC.
    Inventors: Hiroki Ueda, Yoshihiro Shimizu, Shoko Harada, Katsuhiko Matsumoto
  • Patent number: 11261441
    Abstract: The invention provides improved gene therapy vectors, compositions, and methods.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 1, 2022
    Assignees: bluebird bio, Inc., Children's Medical Center Corporation
    Inventors: Gabor Veres, David A. Williams
  • Patent number: 11253598
    Abstract: Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: February 22, 2022
    Inventors: Hye Yeong Nam, Bong-Oh Kim, Min-Hyo Seo, Ji-Yeon Son, Ji-Hye Choi, Sang Hoon Kim
  • Patent number: 11252965
    Abstract: The present invention provides a novel class of insecticides for control of disease vector insects, particularly mosquitoes. These insecticides prevent maturation or development of larvae into adult insects using interfering RNA (iRNA). The present invention further includes compositions comprising iRNA and methods of controlling, reducing, or treating an insect infestation with the iRNA or compositions described herein.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: February 22, 2022
    Assignees: Indiana University Research and Technology Corporation, University of Notre Dame Du Lac
    Inventors: Molly Duman Scheel, David W. Severson, Kathleen Eggleson, Na Wei
  • Patent number: 11249071
    Abstract: Methods of prohibiting Xist-dependent silencing of X chromosome genes include targeting the required Xist silencing complex components including SHARP, SMRT, HDAC3, SAF-A, LBR, and the respective binding sites of SHARP, LBR, and SAF-A on Xist, thereby prohibiting Xist repression, allowing for reactivation of the silenced X chromosome genes.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: February 15, 2022
    Assignee: California Institute of Technology
    Inventors: Mitchell Guttman, Chun-Kan Chen, Colleen A. McHugh
  • Patent number: 11230707
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 25, 2022
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Kevin Flanigan, Adeline Vulin-Chaffiol, Nicolas Wein
  • Patent number: 11214803
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: January 4, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 11203755
    Abstract: An objective of the present invention is to provide a chemically-modified siRNA that has polydeoxyadenylic acid added to the 5? end of the sense strand, and, when complexed with schizophyllan, is high in resistance against RNase and moreover effectively exhibits RNAi activity. To achieve the objective, in the chemically-modified siRNA with polydeoxyadenylic acid added to the 5? end of the sense strand, specific chemical modification is performed for dinucleotide sequences of CA, UA, and UG in the base sequence of the sense strand and dinucleotide sequences of CA, UA, and UG in the base sequence at and after the eighth base from the 5? end of the antisense strand.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: December 21, 2021
    Assignee: NapaJen Pharma, Inc.
    Inventors: Sadaharu Higuchi, Atsushi Uno, Hironori Ando
  • Patent number: 11198870
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 14, 2021
    Assignee: THERMO FISHER SCIENTIFIC INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 11197936
    Abstract: Codon optimized nucleic acid sequences for RDH12 are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequence for functional RDH12. Recombinant vectors are provided that express the codon optimized, functional RDH12. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence, deficiency or inappropriate expression of RDH12. Other compositions and methods are providing for correcting a non-functional, defective or inadequately expressed native RDH12.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: December 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jean Bennett, Junwei Sun, Vidyullatha Vasireddy
  • Patent number: 11198864
    Abstract: The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: December 14, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Sherry Lynn La Porte, Stephen James Moore, James William West
  • Patent number: 11197883
    Abstract: Disclosed herein are UBAP2L targeting agents and use of such agents for the treatment of a neurodegenerative disorder. Further disclosed herein are methods of monitoring the progression of a neurodegenerative disorder and methods of determining the efficacy of a neurodegenerative disorder therapy.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 14, 2021
    Assignee: The Regents of the University of California
    Inventors: Eugene Yeo, Sebastian Markmiller, En-Ching Luo
  • Patent number: 11193128
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: December 7, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Patent number: 11186835
    Abstract: Provided herein, in some embodiments, are artificial ribosomes that synthesize nonribosomal peptides, polyketides, and fatty acids with full control over peptide sequence. Also provided herein are methods for programmed synthesis of nonribosomal peptides, polyketides, and fatty acids. In particular, provided herein are methods for scalable synthesis of a wide range of antibacterial, antifungal, antiviral, and anticancer compounds.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: November 30, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventor: Alexander A. Green
  • Patent number: 11179411
    Abstract: An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: November 23, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Haruhisa Inoue, Keiko Imamura, Kosuke Matsuzono